Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Xiongxiong Cai, Yijian Ying, Chi Zhang, Rong Xu, Baolin Xu, Dongdong Xia
OBJECTIVE: We established an orthopedic ward fracture liaison services (OWFLS) model and evaluated its role in improving detection rates of bone metabolic markers, treatment rates, and long-term treatability. METHODS: This observational retrospective cohort study included 120 patients aged >50 years hospitalized for primary osteoporotic fracture from January 2018 to January 2019 (group A: not included in OWFLS). Group B (included in OWFLS) comprised 120 patients from February 2019 to February 2020...
April 2024: Journal of International Medical Research
#2
Jawaher J Alotaibi, Bushra Albuqami, Wadha Alotaibi, Rawan M Al Ghamdi, Mohammed Alaskar, Hadi Kuriry, Nasser Almasri
This report described a patient not known to have a hepatic disease, found to have a drug-induced autoimmune hepatitis from denosumab. This is an unreported side effect, and here, we presented the possible predisposing factors and suggested monitoring parameters.
April 2024: Clinical Case Reports
#3
JOURNAL ARTICLE
Salvatore Minisola, Cristiana Cipriani, Luciano Colangelo, Jessica Pepe
A 47-year-old postmenopausal woman with osteoporosis was treated with denosumab, which was discontinued due to side effects. She was therefore transitioned to a yearly intravenous infusion of zoledronic acid. An increase in bone turnover markers together with bone loss at the lumbar spine was observed before the second infusion, suggesting an overshooting of bone resorption due to denosumab discontinuation. On physical examination, the patient was restless and reported having lost about 10 kg since the last visit...
March 4, 2024: Journal of Bone and Mineral Research
#4
JOURNAL ARTICLE
Anna M Rzepka, Angela M Cheung, Sandra Kim, Tara Gomes, Suzanne M Cadarette
Timely administration of denosumab every 6 mo is critical in osteoporosis treatment to avoid multiple vertebral fracture risk upon denosumab discontinuation or delay. This study aimed to estimate the immediate and prolonged impact of the COVID-19 pandemic on the timing of denosumab doses. We identified older adults (≥66 yr) residing in the community who were due to receive denosumab between January 2016 and December 2020 using Ontario Drug Benefit data. We completed an interrupted time-series analysis to estimate the impact of the COVID-19 pandemic (March 2020) on the monthly proportion of on-time denosumab doses (183 +/-30 d)...
May 2024: JBMR Plus
#5
JOURNAL ARTICLE
Amil R Agarwal, Matthew J Kinnard, Christopher Murdock, Amy Y Zhao, Uzoma Ahiarakwe, Jordan S Cohen, Kendall F Moseley, Gregory J Golladay, Savyasachi C Thakkar
UNLABELLED: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF). Our study evaluated the economic viability of treatment in patients following arthroplasty and demonstrates that treatment with oral bisphosphonates can be cost-effective in preventing PPF. INTRODUCTION: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF)...
April 15, 2024: Osteoporosis International
#6
JOURNAL ARTICLE
Eng Hooi Tan, Trishna Rathod-Mistry, Victoria Y Strauss, James O'Kelly, Francesco Giorgianni, Richard Baxter, Vanessa C Brunetti, Alma Becic Pedersen, Vera Ehrenstein, Daniel Prieto-Alhambra
Evidence on the comparative effectiveness of osteoporosis treatments is heterogeneous. This may be attributed to different populations and clinical practice, but also to differing methodologies ensuring comparability of treatment groups before treatment effect estimation and the amount of residual confounding by indication. This study assessed the comparability of denosumab vs oral bisphosphonate (OBP) groups using propensity score (PS) methods and negative control outcome (NCO) analysis. A total of 280 288 women aged ≥50 years initiating denosumab or OBP in 2011-2018 were included from the UK Clinical Practice Research Datalink (CPRD) and the Danish National Registries (DNR)...
April 15, 2024: Journal of Bone and Mineral Research
#7
JOURNAL ARTICLE
Makiko Go, Yoshihiro Noguchi, Rikuto Masuda, Hiroki Asano, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura
The most common toxicities associated with cyclin-dependent kinase (CDK) 4/6 inhibitor therapy include decreased leukopenia and neutropenia due to the inhibition of CDK6 of leukocyte and neutrophil precursors in bone marrow. These hematological toxicities are more commonly observed with palbociclib administration than with abemaciclib administration, which is approximately 13 times more selective against CDK4 than CDK6. Thus, even though both successfully inhibit CDK4/6, the side effects of palbociclib and abemaciclib differ due to differences in selectivity...
April 15, 2024: International Journal of Cancer. Journal International du Cancer
#8
JOURNAL ARTICLE
Darran Mc Donald, Matthew T Drake, Rachel K Crowley
Hypercalcaemia of malignancy (HCM) is a common metabolic complication of advanced malignancies with a prevalence varying from 2-30%, depending on cancer type and disease stage. HCM is associated with impaired quality of life, increased risk of hospitalisation and limited survival. Evidence-based guidelines for management of HCM have been lacking to date, despite its prevalence and detrimental impact. This concise guidance highlights key recommendations from the recent Endocrine Society Clinical Practice Guidelines on Treatment of Hypercalcaemia of Malignancy in Adults, published in December 2022...
September 2023: Clinical Medicine: Journal of the Royal College of Physicians of London
#9
JOURNAL ARTICLE
K McCarroll, T Carroll, M Neville, D Fitzpatrick, R Lannon
INTRODUCTION: Transient hypercalcaemia due to teriparatide occurs in up to 11% of patients though delayed hypercalcaemia (> 24 h post injection) is rare. We report the case of a female who developed significant delayed hypercalcaemia after teriparatide treatment for osteoporosis and review other cases in the literature to date. CASE REPORT: A 72-year-old female on teriparatide for the treatment of osteoporosis was found to have hypercalcaemia (3.30 mmol/l) on routine testing approximately 3 months after starting therapy...
April 13, 2024: Osteoporosis International
#10
REVIEW
Joyce Tin Wing Li, Yiu Yan Leung
Background: This systematic review aimed to evaluate the impact of antiresorptive drug therapy on osseointegrated dental implants and the association with medication-related osteonecrosis of the jaw (MRONJ). Methods: A systematic search, including a computer search of several databases with specific keywords, a reference search, and a manual search of four key maxillofacial journals were performed. Relevant articles were then evaluated and those that fulfilled the five predetermined criteria were chosen to enter the final review...
April 3, 2024: Journal of Clinical Medicine
#11
JOURNAL ARTICLE
Seong Son, Michael Y Oh, Byung-Rhae Yoo, Han-Byeol Park
Background : The comparison of the efficacy of zoledronate and denosumab for treating osteoporosis is controversial, and few randomized controlled trials have compared these two drugs in practical patients with acute osteoporotic vertebral compression fractures (OVCFs). We conducted a randomized controlled study to compare the efficacy of zoledronate and denosumab in patients with acute OVCF, with a focus on the occurrence of new OVCF. Methods : We enrolled 206 subjects who had their first acute OVCF, without any previous history of osteoporosis medication...
April 1, 2024: Journal of Clinical Medicine
#12
JOURNAL ARTICLE
Giorgia Grassi, Alberto Ghielmetti, Marta Zampogna, Iacopo Chiodini, Maura Arosio, Giovanna Mantovani, Cristina Eller Vainicher
BACKGROUND: After Denosumab (Dmab) discontinuation C-terminal telopeptide (CTX) levels increase, bone mineral density (BMD) decreases and multiple vertebral fractures (FX) may occur with relevant impact on women's health. A sequential therapy with bisphosphonates is recommended and the European Calcified Tissue Society (ECTS) proposed repeated zoledronate (ZOL) administrations in patients with persistently high CTX levels, although the efficacy of this schedule is unknown. In this retrospective study we describe BMD changes and FX rate in 52 patients managed according to the ECTS recommendations...
April 13, 2024: Journal of Clinical Endocrinology and Metabolism
#13
JOURNAL ARTICLE
Mafo Kamanda-Kosseh, Stephanie Shiau, Sanchita Agarwal, Ananya Kondapalli, Ivelisse Colon, Nayoung Kil, Mariana Bucovsky, Joan M Lappe, Julie Stubby, Elizabeth Shane, Adi Cohen
CONTEXT: We previously reported that sequential teriparatide followed by denosumab substantially increases BMD in premenopausal idiopathic osteoporosis (PremenIOP). OBJECTIVE: To determine whether administration of bisphosphonates after denosumab cessation is associated with stable BMD in PremenIOP. DESIGN: Open-label extension study. PARTICIPANTS: 24 PremenIOP Teriparatide-Denosumab Study participants. INTERVENTIONS: Oral alendronate (ALN), 70mg weekly, or IV zoledronic acid (ZOL), 5mg once (patient choice), was administered 7 months (M) after final denosumab dose...
April 12, 2024: Journal of Clinical Endocrinology and Metabolism
#14
REVIEW
Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves E Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andrade Mota, Bruno Santucci, Daniel da Motta Girardi, Daniel Herchenhorn, Daniel Vilarim Araújo, Denis Leonardo Jardim, Diogo Assed Bastos, Diogo Rodrigues Rosa, Fabio A Schutz, Fábio Roberto Kater, Felipe da Silva Marinho, Fernando Cotait Maluf, Fernando Nunes Galvão de Oliveira, Fernando Vidigal, Igor Alexandre Protzner Morbeck, Jose Augusto Rinck Júnior, Leonardo Atem G A Costa, Manuel Caitano Dias Ferreira Maia, Manuela Zereu, Marcelo Roberto Pereira Freitas, Mariane Sousa Fontes Dias, Milena Shizue Tariki, Pamela Muniz, Patrícia Medeiros Milhomem Beato, Paulo Sérgio Moraes Lages, Pedro Isaacsson Velho, Ricardo Saraiva de Carvalho, Rodrigo Coutinho Mariano, Sandro Roberto de Araújo Cavallero, Thiago Martins Oliveira, Vinicius Carrera Souza, Oren Smaletz, Stênio de Cássio Zequi
PURPOSE: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. METHODS: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours...
April 9, 2024: Journal of Cancer Research and Clinical Oncology
#15
JOURNAL ARTICLE
Hyunsook Kim, Eun Ju Lee, Siyun Woo, Sohee Rho, Ji Yong Jung
Background : Osteoporosis is common in hemodialysis (HD) patients, contributing to cardiovascular risks. Limited research exists on denosumab's efficacy in this group. Our study explores denosumab's effects on bone turnover markers (BTMs) and vascular calcification in chronic kidney disease-mineral bone disorder (CKD-MBD) patients. Methods : In a prospective single-center study, we investigated the effects of denosumab over 2 years on 30 HD patients from a cohort of 185. Annual assessments of bone mineral density (BMD), vascular calcification, and health-related quality of life (HRQL) were conducted and compared with an untreated group...
March 2, 2024: Journal of Clinical Medicine
#16
Taiki Yasukawa, Sang Yang Lee, Hiro Hasegawa, Koki Tsuchiya, Toshiyuki Shirahata, Makoto Yoshimura, Yoshifumi Kudo
Atypical femoral fractures (AFFs) occur with minor trauma and are believed to be a potential complication of the prolonged use of antiresorptive agents, such as bisphosphonate and denosumab, for the treatment of bone metastasis. In comparison with typical femoral fractures, AFFs have a higher incidence of complications, including implant failure and delayed union or nonunion. This report describes the case of a 42-year-old woman who developed denosumab-associated AFF after denosumab therapy for bone metastasis from breast cancer...
June 2024: Trauma Case Reports
#17
JOURNAL ARTICLE
Raj Singh, Sreekumar Madasswery, Matt Colman, Paul McKeegan Kent
Aneurysmal bone cyst (ABC) is a non-malignant, locally destructive, blood-filled lesion in the bone that tends to grow aggressively. A young girl presented with a rapid recurrence after aggressive surgery of a large symptomatic sacral-spinal ABC. After a multidisciplinary tumour board, she was successfully treated with sclerotherapy and monthly intravenous denosumab. The patient has maintained asymptomatic for over 36 months now and has returned to full activity and strength. She never required surgery and has had radiologic resolution of the lesions...
April 8, 2024: BMJ Case Reports
#18
JOURNAL ARTICLE
Akiko Yamamoto, Masashi Nagao, Yuji Nishizaki, Eri Maeda, Muneaki Ishijima
BACKGROUND AND AIMS: To investigate the factors associated with changes in bone mineral density (BMD) and the incidence of fractures in osteoporotic patients treated with denosumab. METHODS: This retrospective study included 162 osteoporotic patients treated with denosumab for 24 months between 2013 and 2019. Patients were divided according to the changes in BMD as nonresponders (NL group: <3% increase in lumbar spine BMD [LBMD], NH group: <0% increase in femoral neck BMD [FNBMD]) or responders (RL group: ≥3% increase in LBMD, RH group: ≥0% increase in FNBMD)...
April 2024: Health Science Reports
#19
JOURNAL ARTICLE
Katharina Theresa Obermeier, Ina Dewenter, Yoana Malenova, Riham Fliefel, Gabriele Kaeppler, Sven Otto
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction associated with antiresorptive drugs such as bisphosphonates and denosumab. When dealing with advanced and/or multiple MRONJ lesions undergoing surgical therapy, the extent of surgery is often a topic of discussion. The aim of this study was to identify the differences in bone density in and around the MRONJ lesion before and after surgical treatment to evaluate the needed surgical extend of the modelling osteotomy. In this retrospective study 26 patients with MRONJ lesions that were surgically treated in our department were observed...
April 4, 2024: Scientific Reports
#20
JOURNAL ARTICLE
J Lane, B Langdahl, M Stone, A Kurth, M Oates, J Timoshanko, Z Wang, C Libanati, F Cosman
UNLABELLED: Post hoc analysis of FRAME and ARCH revealed that on-study nonvertebral and vertebral fractures by Month 12 were less common in women initially treated with romosozumab versus placebo or alendronate. Recurrent fracture risk was also lower in romosozumab‑treated patients, and there were no fracture‑related complications. Results support continuing romosozumab treatment post‑fracture. PURPOSE: Post hoc analysis evaluating efficacy and safety of romosozumab, administered in the immediate post‑fracture period, in the FRAME and ARCH phase 3 trials...
April 4, 2024: Osteoporosis International
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
